Ironwood Pharmaceuticals earnings release, August 6, 2026
FOR
IMMEDIATE RELEASE
Ironwood Pharmaceuticals
Raises 2026 Full-Year Financial Guidance Building on
Strong Second
Quarter Results – Raises full-year 2026 LINZESS®
(linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than
30% increase year-over-year; Raises total revenue guidance to $460 - $485 million and adjusted EBITDA guidance to greater than $310 million – – Q2 2026
LINZESS U.S. net sales of $282 million; $555 million year-to-date representing 44% year-over-year growth – – Total revenue of $113 million, GAAP net income of $51 million and adjusted EBITDA of $83 million in Q2 2026; repaid $200 million convertible notes with cash on hand – – Confirmatory
Phase 3 STARS-2 trial of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) now actively recruiting patients – BOSTON, Mass., August 6, 2026 — Ironwood Pharmaceuticals, Inc.
(Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2026 results and recent business performance.
“Throughout the first half of the year, we have remained laser focused on meaningful execution of our three strategic priorities: maximizing LINZESS, advancing apraglutide, and delivering sustained profits and cash flows,” said Tom McCourt, chief executive officer of Ironwood. “We are pleased to report a second consecutive quarter of strong performance for LINZESS, fueled by improved net price and mid-single digit prescription demand growth which supported our decision to raise our full-year 2026 financial guidance. We also repaid our $200 million convertible notes during the quarter using cash on hand and remain committed to further debt reduction and strengthening our balance sheet through year end.”
“Importantly, we initiated STARS-2 and are actively recruiting patients in this confirmatory Phase 3 trial of apraglutide with the goal that it will be the first long-acting
GLP-2 analog to market. Based on the positive Phase 3 STARS data and the confirmatory design of STARS-2, we are confident that apraglutide has the potential to be a best-in-class therapy for people with short bowel syndrome with intestinal failure, a condition with significant unmet need,” McCourt continued. “With Dr. Jeffrey Silber now serving as chief medical officer and head of research and drug development, his proven clinical development leadership further strengthens our ability to advance apraglutide and bring it to patients as quickly as possible.”
Second Quarter 2026
Financial Highlights¹
(in thousands, except for per share amounts)¹
Refer to the Reconciliation of GAAP Results to Non-GAAP Financial Measures table and to the Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA table at the end of this press release. Refer to Non-GAAP Financial Measures for additional information.
Second Quarter Corporate
Highlights
U.S. LINZESS²
Apraglutide³
Corporate Updates
Second Quarter 2026
Financial Results⁴⁵¹
Ironwood’s U.S. collaborative arrangements revenue includes reimbursement from AbbVie for a portion of Ironwood’s commercial expenses related to sales of LINZESS in the U.S.²
Adjusted EBITDA is calculated by subtracting stock-based compensation, net restructuring expenses, net interest expense, income taxes, and depreciation and amortization from GAAP net income (loss). For purposes of this guidance, we have assumed that Ironwood will not incur material expenses related to business development activities in 2026. Ironwood does not provide guidance on GAAP net income or a reconciliation of expected adjusted EBITDA to expected GAAP net income because, without unreasonable efforts, it is unable to predict with reasonable certainty the non-GAAP adjustments used to calculate adjusted EBITDA. These adjustments are uncertain, depend on various factors and could have a material impact on GAAP net income for the guidance period. Management believes this non-GAAP information is useful for investors, taken in conjunction with Ironwood’s GAAP financial statements, because it provides greater transparency and period-over-period comparability with respect to Ironwood’s operating performance. These measures are also used by management to assess the performance of the business. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP. In addition, these non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies.
Non-GAAP Financial Measures
Ironwood presents non-GAAP net income
(loss) and non-GAAP net income (loss) per share to exclude amortization of acquired intangible assets, and net restructuring expenses, all net of tax effect. Non-GAAP adjustments are further detailed below:
Management believes this non-GAAP information is useful for investors, taken in conjunction with Ironwood’s GAAP financial statements, because it provides greater transparency and period-over-period comparability with respect to Ironwood’s operating performance. These measures are also used by management to assess the performance of the business. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP. In addition, these non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. For a reconciliation of non-GAAP net income (loss)... (truncated) (loss) and GAAP net income (loss) per share, respectively, and for a reconciliation of adjusted EBITDA to GAAP net income (loss), please refer to the tables at the end of this press release.⁶
Ironwood does not provide guidance on
GAAP net income or a reconciliation of expected adjusted EBITDA to expected GAAP net income because, without unreasonable efforts, it is unable to predict with reasonable certainty the non-GAAP adjustments used to calculate adjusted EBITDA. These adjustments are uncertain, depend on various factors and could have a material impact on GAAP net income for the guidance period.
Conference Call Information
Ironwood will host a conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6 th, 2026, to discuss its second quarter results and recent business activities. Individuals interested in participating in the call should dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) using conference ID number and event passcode 3647053. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, August 6, 2026, at approximately
11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, August 20, 2026. To listen to the replay, dial (800) 770-2030 (U.S. and Canada) using conference ID number 3647053. The archived webcast will be available on Ironwood’s website for one year beginning approximately one hour after the call has completed.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs.
Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.
We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on
X and on
LinkedIn.
About LINZESS (Linaclotide)
LINZESS® is the #1 prescribed brand in the U.S. for the treatment of patients with irritable bowel syndrome with constipation (“IBS-C”) or chronic idiopathic constipation (“CIC”), based on IQVIA data. LINZESS is a once-daily capsule that helps relieve the abdominal pain and constipation associated with IBS-C in adults and pediatric patients 7 years of age and older. LINZESS has also been shown to relieve constipation, infrequent stools, hard stools, straining and incomplete evacuation associated with CIC in adult patients. LINZESS relieves constipation in children and adolescents aged 2 to 17 years with functional constipation.⁷
LINZESS is not a laxative; it is the first medicine approved by the FDA in a class called GC-C agonists. LINZESS contains a peptide called linaclotide that activates the
GC-C receptor in the intestine. Activation of GC-C is thought to result in increased intestinal fluid secretion and accelerated transit and a decrease in the activity of pain-sensing nerves in the intestine. The clinical relevance of the effect on pain fibers, which is based on nonclinical studies, has not been established.
In the United States, Ironwood and AbbVie co-develop and co-commercialize LINZESS for the treatment of IBS-C in adults and pediatric patients 7 years of age and older,
CIC in adults and functional constipation (FC) in pediatric patients 2 years of age and older. In Europe, AbbVie markets linaclotide under the brand name CONSTELLA® for the treatment of adults with moderate to severe IBS-C. In Japan, Ironwood's partner, Astellas, markets linaclotide under the brand name LINZESS for the treatment of adults with IBS-C or CIC. Ironwood also has partnered with Grand
Life Sciences for development and commercialization of LINZESS in China, and with AbbVie for development and commercialization of linaclotide in all other territories worldwide.
LINZESS Important
Safety Information
INDICATIONS AND USAGE
LINZESS® (linaclotide) is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older, chronic idiopathic constipation (CIC) in adults, and functional constipation (FC) in pediatric patients 2 years of age and older.
IMPORTANT SAFETY INFORMATION
Contraindications⁸
Warnings and Precautions
Risk of Serious Dehydration in Pediatric
Patients Less Than 2 Years of Age
Diarrhea
Common Adverse Reactions
(incidence
≥2% and greater than placebo)
Please see full Prescribing Information including Boxed Warning: https://www.rxabbvie.com/pdf/linzess_pi.pdf
LINZESS® and CONSTELLA® are registered trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to in this press release are the property of their respective owners. All rights reserved.⁹
Financial statements
Income Statement
(in thousands, except for per share amounts)
| Q2 2026 | Q2 2025 | |
|---|---|---|
| Total revenue | 113,041 | 85,239 |
| Total costs and expenses | 33,734 | 39,918 |
| GAAP net income | 51,291 | 23,599 |
| GAAP net income – per share basic | 0.31 | 0.15 |
| GAAP net income – per share diluted | 0.31 | 0.14 |
| Adjusted EBITDA1 | 83,042 | 50,101 |
| Non-GAAP net income | 51,495 | 23,623 |
| Non-GAAP net income per share – basic | 0.31 | 0.15 |
| Non-GAAP net income per share – diluted | 0.31 | 0.14 |
Income Statement
Prior 2026 Guidance (May 2026) — Second Quarter 2026 Financial Results
| Prior 2026 Guidance (May 2026) – $1.125 to $1.175 billion Driven by improved net price and low-single digit percentage demand growth | Updated 2026 Guidance (August 2026) – $1.15 to $1.20 billion Driven by improved net price and mid-single digit percentage demand growth | |
|---|---|---|
| Total Revenue1 | $450 to $475 million | $460 to $485 million |
| Adjusted EBITDA2 | >$300 million | >$310 million |
Income Statement
Three Months Ended June 30, — (unaudited) (in thousands)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Total revenues | 113,041 | 85,239 | 219,547 | 126,382 | |
| Costs and expenses: | Research and development | 22,421 | 23,373 | 44,361 | 50,805 |
| Costs and expenses: | Selling, general and administrative | 11,313 | 16,795 | 23,346 | 41,055 |
| Costs and expenses: | Restructuring, net | -250 | -40 | 18,309 | |
| Costs and expenses: | Total costs and expenses | 33,734 | 39,918 | 67,667 | 110,169 |
| Costs and expenses: | Income from operations | 79,307 | 45,321 | 151,880 | 16,213 |
| Other income (expense): | Interest expense and other financing costs | -7,203 | -8,356 | -16,344 | -16,426 |
| Other income (expense): | Interest and investment income | 1,585 | 818 | 3,283 | 1,687 |
| Other income (expense): | Other | 42 | 39 | 84 | 76 |
| Other income (expense): | Other income (expense), net | -5,576 | -7,499 | -12,977 | -14,663 |
| Other income (expense): | Income before income taxes | 73,731 | 37,822 | 138,903 | 1,550 |
| Other income (expense): | Income tax expense | -22,440 | -14,223 | -46,839 | -15,337 |
| Other income (expense): | GAAP net income (loss) | 51,291 | 23,599 | 92,064 | -13,787 |
| Other income (expense): | GAAP net income (loss) per share—basic | 0.31 | 0.15 | 0.56 | -0.09 |
| Other income (expense): | GAAP net income (loss) per share—diluted | 0.31 | 0.14 | 0.55 | -0.09 |
Income Statement
Three Months Ended June 30, — A reconciliation of GAAP net income (loss) to adjusted EBITDA:
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| GAAP net income (loss) | 51,291 | 23,599 | 92,064 | -13,787 | |
| Adjustments: | Stock-based compensation | 3,236 | 4,524 | 6,889 | 9,815 |
| Adjustments: | Restructuring expenses, net | -250 | -40 | 18,309 | |
| Adjustments: | Interest expense | 7,203 | 8,356 | 16,344 | 16,426 |
| Adjustments: | Interest and investment income | -1,585 | -818 | -3,283 | -1,687 |
| Adjustments: | Income tax expense | 22,440 | 14,223 | 46,839 | 15,337 |
| Adjustments: | Depreciation and amortization | 457 | 467 | 900 | 946 |
| Adjustments: | Adjusted EBITDA1 | 83,042 | 50,101 | 159,713 | 45,359 |
Income Statement
Three Months Ended June 30, — (unaudited) (in thousands)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | |
|---|---|---|---|---|
| LINZESS U.S. net sales as reported by AbbVie2 | 282,309 | 248,001 | 554,834 | 386,478 |
| AbbVie & Ironwood commercial costs, expenses and other discounts3 | 62,987 | 76,886 | 127,614 | 143,793 |
| Commercial profit on sales of LINZESS | 219,322 | 171,115 | 427,220 | 242,685 |
| Commercial Margin4 | 78.0% | 69.0% | 77.0% | 63.0% |
| Ironwood’s share of net profit | 109,661 | 85,558 | 213,610 | 121,343 |
| Reimbursement for Ironwood’s commercial expenses5 | 384 | 125 | 657 | 3,108 |
| Ironwood’s U.S. collaborative arrangements revenue | 110,045 | 85,683 | 214,267 | 124,451 |
Balance Sheet
June 30, 2026 — (unaudited) (in thousands)
| June 30, 2026 | December 31, 2025 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 79,127 | 215,456 |
| Current assets: | Accounts receivable, net | 112,732 | 46,745 |
| Current assets: | Prepaid expenses and other current assets | 7,342 | 11,977 |
| Current assets: | Total current assets | 199,201 | 274,178 |
| Current assets: | Property and equipment, net | 2,913 | 3,408 |
| Current assets: | Operating lease right-of-use assets | 8,443 | 9,340 |
| Current assets: | Intangible assets, net | 1,633 | 2,040 |
| Current assets: | Deferred tax assets | 69,064 | 103,433 |
| Current assets: | Other assets | 3,874 | 4,502 |
| Current assets: | Total assets | 285,128 | 396,901 |
| Current liabilities: | Accounts payable | 911 | 2,898 |
| Current liabilities: | Accrued research and development costs | 3,124 | 3,149 |
| Current liabilities: | Accrued expenses and other current liabilities | 25,534 | 33,239 |
| Current liabilities: | Current portion of operating lease liabilities | 3,285 | 3,252 |
| Current liabilities: | Current portion on convertible senior notes | 199,680 | |
| Current liabilities: | Total current liabilities | 32,854 | 242,218 |
| Current liabilities: | Operating lease obligations, net of current portion | 8,581 | 9,870 |
| Current liabilities: | Revolving credit facility | 385,000 | 385,000 |
| Current liabilities: | Other liabilities | 20,536 | 21,648 |
| Current liabilities: | Total liabilities | 446,971 | 658,376 |
| Current liabilities: | Total stockholders’ deficit | -161,843 | -261,835 |
| Current liabilities: | Total liabilities and stockholders’ deficit | 285,128 | 396,901 |
Full release
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about Ironwood’s ability to execute on its mission; Ironwood’s... (truncated); Ironwood’s ability to drive growth and profitability; the commercial potential of LINZESS; Ironwood’s financial performance and results, and guidance and expectations related thereto; LINZESS prescription demand growth, LINZESS U.S. net sales, total revenue and adjusted EBITDA in 2026; our commitment to further debt reduction and strengthening our balance sheet and the timing to achieve thereof; anticipated recruitment in our STARS-2 trial; the goal of bringing the first long-acting, once-weekly GLP-2 analog to market; and our belief that apraglutide has the potential to become a best-in-class, long-acting GLP-2 therapy for people with SBS-IF. These forward-looking statements speak only as of the date of this press release, and Ironwood undertakes no obligation to update these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those related to the effectiveness of development and commercialization efforts by us and our partners; preclinical and clinical development, manufacturing and formulation development of linaclotide, apraglutide, and our other product candidates; the risk of uncertainty relating to pricing and reimbursement policies in the U.S., which, if not favorable for our products, could hinder or prevent our products’ commercial success; the risk that clinical programs and studies, including for apraglutide, may not progress or develop as anticipated, including that studies are delayed or discontinued for any reason, such as safety, tolerability, enrollment, manufacturing, economic or other reasons; the risk that findings from our completed nonclinical studies and clinical trials may not be replicated in later trials and earlier-stage clinical trials may not be predictive of the results we may obtain in later-stage clinical trials or of the likelihood of regulatory approval; the risk that apraglutide will not be approved by the FDA or other regulatory agencies; the risk of competition or that new products may emerge that provide different or better alternatives for treatment of the conditions that our products are approved to treat; the risk that healthcare reform and other governmental and private payor initiatives may have an adverse effect upon or prevent our products’ or product candidates’ commercial success; the efficacy, safety and tolerability of linaclotide and our product candidates; the risk that the commercial and therapeutic opportunities for LINZESS, apraglutide or our other product candidates are not as we expect; decisions by regulatory and judicial authorities; the risk we may never get additional patent protection for linaclotide, apraglutide and other product candidates, that patents for linaclotide, apraglutide or other products may not provide adequate protection from competition, or that we are not able to successfully protect such patents; the risk that we are unable to manage our expenses or cash use, or are unable to commercialize our products as expected; the risk that the development of apraglutide is not successful or that any of our product candidates does not receive regulatory approval or is not successfully commercialized; outcomes in legal proceedings to protect or enforce the patents relating to our products and product candidates, including abbreviated new drug application litigation; the risk that financial and operating results may differ from our projections; developments in the intellectual property landscape; challenges from and rights of competitors or potential competitors; the risk that our planned investments do not have the anticipated effect on our company revenues; developments in accounting guidance or practice; Ironwood’s or AbbVie’s accounting practices, including reporting and settlement practices as between Ironwood and AbbVie; the risk that our indebtedness could adversely affect our financial condition or restrict our future operations; and the risks listed under the heading “Risk Factors” and elsewhere in our Annual
Report on Form 10-K for the year ended December 31, 2025, and in our subsequent Securities and Exchange Commission filings.¹⁰
Investors and Media:
Chris Stamm
Vice President, Investor Relations and Communications cstamm@ironwoodpharma.com
Investors:
Precision AQ
Stephanie Ascher
Stephanie.Ascher@precisionaq.com¹¹
Condensed
Consolidated Balance Sheets
(In thousands)
(unaudited)¹²
Condensed
Consolidated Statements of Income (Loss)
(In thousands, except per share amounts)
(unaudited)¹³
Reconciliation of GAAP Results to Non-GAAP Financial Measures
(In thousands, except per share amounts) (unaudited)
A reconciliation between net income (loss) on a GAAP basis and on a non-GAAP basis is as follows:
A reconciliation between basic net income
(loss) per share on a GAAP basis and on a non-GAAP basis is as follows:¹⁴
A reconciliation between diluted net income (loss) per share on a GAAP basis and on a non-GAAP basis is as follows:¹⁵
Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA
(In thousands)
(unaudited)
A reconciliation of GAAP net income
(loss) to adjusted EBITDA:¹
Adjusted EBITDA is calculated by subtracting net restructuring expenses, net interest expense, income taxes, depreciation and amortization and stock-based compensation, from GAAP net income.¹⁶
U.S. LINZESS
Commercial Collaboration¹
Revenue/Expense
Calculation
(In thousands)
(unaudited)¹
The purpose of this table is to present calculations of Ironwood’s share of net profit (loss) generated from the sales of LINZESS in the U.S. and Ironwood’s... (truncated)ed to LINZESS in the U.S. that are shared equally between the parties under the collaboration agreement. Please refer to the table at the end of this press release for net profit for the U.S. LINZESS brand collaboration with AbbVie.²
LINZESS net sales are recognized using AbbVie’s revenue recognition accounting policies and reporting conventions. As a result, certain rebates and discounts are classified as LINZESS U.S. commercial costs, expenses and other discounts within Ironwood’s calculation of collaborative arrangements revenue.³
Includes certain discounts recognized and cost of goods sold incurred by AbbVie; also includes commercial costs incurred by AbbVie and Ironwood that are attributable to the cost-sharing arrangement between the parties.⁴
Commercial margin is defined as commercial profit on sales of LINZESS as a percent of total LINZESS U.S. net sales.⁵
Year-over-year decrease reflects impact of the reduction to Ironwood’s commercial expenses and corresponding reimbursement from AbbVie due to Ironwood’s strategic reorganization announced in January 2025.¹⁷
US LINZESS Full
Brand Collaboration¹
Revenue/Expense
Calculation
(In thousands)
(unaudited)¹
Ironwood collaborates with
AbbVie on the development and commercialization of linaclotide in North America. Under the terms of the collaboration agreement, Ironwood receives 50% of the net profits and bears 50% of the net losses from the commercial sale of LINZESS in the U.S. The purpose of this table is to present calculations of the total net profit (loss) generated from the sales of LINZESS in the U.S., including the commercial costs and expenses and the research and development expenses related to LINZESS in the U.S. that are shared equally between the parties under the collaboration agreement.²
LINZESS net sales are recognized using AbbVie’s revenue recognition accounting policies and reporting conventions. As a result, certain rebates and discounts are classified as LINZESS U.S. commercial costs, expenses and other discounts within Ironwood’s calculation of collaborative arrangements revenue.³
Includes certain discounts recognized and cost of goods sold incurred by AbbVie; also includes commercial costs incurred by AbbVie and Ironwood that are attributable to the cost-sharing arrangement between the parties.⁴
Expenses related to LINZESS in the U.S. are shared equally between Ironwood and AbbVie under the collaboration agreement.¹⁸